#BEGIN_DRUGCARD DB02137

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
872689-63-9

# ChEBI_ID:
21437

# Chemical_Formula:
C10H10MoN5O8PS2

# Chemical_IUPAC_Name:
5-amino-7,13-dioxo-16-[(phosphonatooxy)methyl]-17-oxa-12,14-dithia-2,4,6,9-tetraaza-13-molybdatetracyclo[8.7.0.0^{3,8}.0^{11,15}]heptadeca-3(8),5,11(15)-trien-13-olate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Absence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage usually leading to death within months of birth, due to the lack of active sulfite oxidase.

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Molybdenum Cofactor

# HET_ID:
PCD

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C10H14N5O6PS2.Mo.2O/c11-10-14-7-4(8(16)15-10)12-3-6(24)5(23)2(21-9(3)13-7)1-20-22(17,18)19;;;/h2-3,9,12,23-24H,1H2,(H2,17,18,19)(H4,11,13,14,15,16);;;/q;+2;;-1/p-4

# InChI_Key:
InChIKey=UCICVTHYJCEWTJ-UHFFFAOYSA-J

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2137

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
519.26

# Molecular_Weight_Mono:
520.876248059

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1SIJ

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.66

# Predicted_LogS:
-1.6

# Predicted_Water_Solubility:
1.61e+01 g/l

# Primary_Accession_No:
DB02137

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936308

# PubChem_Substance_ID:
46505896

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02517

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC(=O)C2=C(NC3OC(COP([O-])([O-])=O)C4=C(S[Mo]([O-])(=O)S4)C3N2)N1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
MoCo

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:50 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Molybdenum_cofactor

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X77222

# Drug_Target_1_GenBank_ID_Protein:
853817

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
mop

# Drug_Target_1_Gene_Sequence:
>2724 bp
ATGATTCAAAAAGTAATCACCGTCAACGGCATCGAGCAGAATCTGTTCGTGGACGCCGAA
GCCCTGCTGTCTGACGTGCTGCGTCAGCAACTCGGGCTCACCGGCGTCAAGGTGGGCTGC
GAACAGGGCCAGTGCGGCGCCTGCTCCGTCATCCTGGATGGCAAAGTGGTGCGCGCCTGC
GTCACCAAAATGAAGCGCGTGGCCGACGGCGCGCAGATCACCACCATCGAAGGCGTGGGC
CAGCCGGAGAACCTGCATCCGTTGCAGAAAGCCTGGGTGCTGCACGGCGGCGCGCAATGC
GGCTTCTGCTCCCCCGGCTTCATCGTCTCCGCCAAGGGCCTCCTGGACACCAACGCCGAC
CCCTCTCGCGAAGACGTGCGTGATTGGTTCCAGAAGCATCGCAATGCTTGCCGTTGCACC
GGCTACAAGCCGCTGGTGGACGCCGTGATGGACGCCGCCGCGGTCATCAATGGCAAGAAG
CCCGAAACCGACCTGGAATTCAAGATGCCCGCCGACGGCCGCATCTGGGGCTCCAAATAC
CCCCGCCCCACGGCCGTGGCCAAGGTCACCGGCACGCTGGACTACGGCGCGGACCTGGGC
CTGAAAATGCCCGCTGGCACCCTGCACTTGGCCATGGTCCAGGCCAAGGTGTCCCACGCC
AACATCAAGGGCATCGACACCTCCGAAGCCCTCACCATGCCCGGCGTCCACAGCGTCATC
ACGCACAAGGACGTCAAGGGCAAGAACCGCATCACCGGCCTCATCACCTTCCCCACCAAC
AAGGGTGACGGCTGGGATCGTCCCATCCTGTGCGACGAAAAGGTCTTCCAGTACGGCGAC
TGCATCGCCCTGGTCTGCGCCGACTCCGAAGCCAACGCCCGCGCCGCGGCCGAAAAGGTG
AAGGTGGACCTGGAAGAACTGCCCGCGTACATGAGCGGCCCTGCCGCTGCGGCCGAGGAT
GCCATTGAGATCCATCCCGGCACGCCCAACGTGTACTTTGAACAGCCCATCGTCAAGGGC
GAAGACACCGGCCCCATCTTCGCCTCGGCCGACGTCACCGTGGAAGGCGACTTCTACGTG
GGCCGCCAGCCGCACATGCCCATCGAACCAGACGTAGCCTTTGCCTACATGGGCGACGAC
GGCAAGTGCTACATCCACTCCAAGTCCATCGGCGTGCACCTGCACCTGTACATGATCGCC
CCCGGCGTGGGCCTGGAACCCGATCAGCTGGTGCTGGTGGCCAACCCCATGGGCGGCACC
TTCGGCTACAAGTTCAGCCCCACCTCCGAAGCCCTGGTGGCCGTGGCGGCCATGGCCACG
GGCCGCCCCGTGCACCTGCGCTACAACTATCAGCAGCAGCAGCAGTACACCGGCAAGCGC
TCCCCGTGGGAAATGAACGTCAAGTTCGCGGCCAAGAAAGACGGCACGCTCCTGGCCATG
GAATCCGACTGGCTGGTGGACCACGGCCCCTACTCGGAATTCGGCGACCTCCTGACCCTG
CGCGGCGCACAGTTCATCGGCGCCGGCTACAACATCCCCAACATCCGCGGCCTCGGTCGC
ACTGTGGCCACCAACCACGTCTGGGGCTCTGCCTTCCGCGGCTACGGTGCGCCTCAGTCC
ATGTTCGCCTCCGAATGTCTCATGGACATGCTGGCGGAAAAGCTGGGCATGGACCCGCTG
GAACTGCGCTACAAGAACGCCTACCGCCCCGGCGACACCAACCCCACCGGCCAGGAACCT
GAAGTCTTCAGCCTGCCGGACATGATCGACCAGCTGCGGCCCAAGTATCAGGCTGCTCTG
GAAAAGGCCCAAAAGGAATCCACCGCCACCCATAAGAAGGGCGTGGGCATCTCCATCGGC
GTGTACGGCAGCGGCCTGGACGGCCCTGACGCCTCCGAAGCCTGGGCCGAGCTCAATGCC
GACGGCACCATCACCGTGCATACGGCCTGGGAAGACCATGGCCAGGGCGCGGACATCGGC
TGCGTGGGCACGGCGCACGAAGCCCTGCGTCCCATGGGCGTGGCTCCGGAAAAGATCAAG
TTCACCTGGCCCAACACCGCCACCACCCCCAACTCCGGCCCCTCCGGAGGCTCCCGCCAG
CAGGTGATGACCGGCAACGCCATCCGCGTGGCCTGTGAAAACCTCCTCAAGGCCTGTGAA
AAGCCCGGCGGCGGCTACTACACCTACGACGAACTGAAAGCCGCGGACAAGCCCACCAAG
ATCACCGGCAACTGGACCGCCAGCGGGGCCACCCACTGCGACGCCGTGACCGGCCTTGGC
AAGCCCTTTGTGGTGTACATGTACGGCGTGTTCATGGCCGAAGTGACCGTGGACGTGGCC
ACCGGCCAGACCACCGTGGACGGCATGACCCTCATGGCCGACCTCGGCAGCCTCTGCAAC
CAGCTGGCCACCGACGGGCAGATCTACGGCGGCCTGGCCCAGGGCATCGGCCTGGCCCTG
TCCGAGGACTTCGAGGACATCAAGAAGCACGCCACCCTCGTGGGCGCGGGCTTCCCGTTC
ATCAAGCAGATCCCGGACAAGCTGGACATCGTGTACGTGAACCATCCGCGTCCGGACGGC
CCCTTCGGCGCTTCCGGTGTGGGCGAACTGCCCCTGACCAGCCCGCACGCGGCCATCATC
AACGCCATCAAGAGCGCCACTGGCGTGCGCATCTACCGCCTCCCGGCCTACCCGGAAAAG
GTGCTGGAAGCCTTGAAGGCCTAA

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
11713686	Rebelo JM, Dias JM, Huber R, Moura JJ, Romao MJ: Structure refinement of the aldehyde oxidoreductase from Desulfovibrio gigas (MOP) at 1.28 A. J Biol Inorg Chem. 2001 Oct;6(8):791-800.
7502041	Romao MJ, Archer M, Moura I, Moura JJ, LeGall J, Engh R, Schneider M, Hof P, Huber R: Crystal structure of the xanthine oxidase-related aldehyde oxido-reductase from D. gigas. Science. 1995 Nov 17;270(5239):1170-6.
8143744	Thoenes U, Flores OL, Neves A, Devreese B, Van Beeumen JJ, Huber R, Romao MJ, LeGall J, Moura JJ, Rodrigues-Pousada C: Molecular cloning and sequence analysis of the gene of the molybdenum-containing aldehyde oxido-reductase of Desulfovibrio gigas. The deduced amino acid sequence shows similarity to xanthine dehydrogenase. Eur J Biochem. 1994 Mar 15;220(3):901-10.
8799115	Huber R, Hof P, Duarte RO, Moura JJ, Moura I, Liu MY, LeGall J, Hille R, Archer M, Romao MJ: A structure-based catalytic mechanism for the xanthine oxidase family of molybdenum enzymes. Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):8846-51.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2656

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
97036

# Drug_Target_1_Name:
Aldehyde oxidoreductase

# Drug_Target_1_Number_of_Residues:
907

# Drug_Target_1_PDB_ID:
1VLB

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00111	Fer2
PF01315	Ald_Xan_dh_C
PF01799	Fer2_2
PF02738	Ald_Xan_dh_C2

# Drug_Target_1_Protein_Sequence:
>Aldehyde oxidoreductase
MIQKVITVNGIEQNLFVDAEALLSDVLRQQLGLTGVKVGCEQGQCGACSVILDGKVVRAC
VTKMKRVADGAQITTIEGVGQPENLHPLQKAWVLHGGAQCGFCSPGFIVSAKGLLDTNAD
PSREDVRDWFQKHRNACRCTGYKPLVDAVMDAAAVINGKKPETDLEFKMPADGRIWGSKY
PRPTAVAKVTGTLDYGADLGLKMPAGTLHLAMVQAKVSHANIKGIDTSEALTMPGVHSVI
THKDVKGKNRITGLITFPTNKGDGWDRPILCDEKVFQYGDCIALVCADSEANARAAAEKV
KVDLEELPAYMSGPAAAAEDAIEIHPGTPNVYFEQPIVKGEDTGPIFASADVTVEGDFYV
GRQPHMPIEPDVAFAYMGDDGKCYIHSKSIGVHLHLYMIAPGVGLEPDQLVLVANPMGGT
FGYKFSPTSEALVAVAAMATGRPVHLRYNYQQQQQYTGKRSPWEMNVKFAAKKDGTLLAM
ESDWLVDHGPYSEFGDLLTLRGAQFIGAGYNIPNIRGLGRTVATNHVWGSAFRGYGAPQS
MFASECLMDMLAEKLGMDPLELRYKNAYRPGDTNPTGQEPEVFSLPDMIDQLRPKYQAAL
EKAQKESTATHKKGVGISIGVYGSGLDGPDASEAWAELNADGTITVHTAWEDHGQGADIG
CVGTAHEALRPMGVAPEKIKFTWPNTATTPNSGPSGGSRQQVMTGNAIRVACENLLKACE
KPGGGYYTYDELKAADKPTKITGNWTASGATHCDAVTGLGKPFVVYMYGVFMAEVTVDVA
TGQTTVDGMTLMADLGSLCNQLATDGQIYGGLAQGIGLALSEDFEDIKKHATLVGAGFPF
IKQIPDKLDIVYVNHPRPDGPFGASGVGELPLTSPHAAIINAIKSATGVRIYRLPAYPEK
VLEALKA

# Drug_Target_1_Reaction:
an aldehyde + H2O + acceptor = a carboxylate + reduced acceptor

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
An aldehyde + H(2)O + acceptor = a carboxylate + reduced acceptor

# Drug_Target_1_SwissProt_ID:
Q46509

# Drug_Target_1_SwissProt_Name:
MOP_DESGI

# Drug_Target_1_Synonyms:
EC 1.2.99.7
Molybdenum iron sulfur protein

# Drug_Target_1_Theoretical_pI:
5.95

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB02137
